Company intelligence / Profile preview

N1 Life

Milpitas, California, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

N1-109 demonstrated nearly 99% elimination efficacy of metastatic tumors in ovarian cancer animal models, superior to standard treatments; dermatological pipelines planned for clinical validation around 2025.

Therapeutic areas: OncologyNeurologyDermatology
Modalities: Peptide-drug conjugateSmall moleculePeptidesPolymer-based deliveryNanoparticle
Industry: Biotech

Partnerships

Nearly 10 domestic and foreign companiesYDS Pharmatech

Beyond the preview

Go deeper on N1 Life.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on N1 Life.

Explore the full profile